• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

鉴定一个免疫相关的风险特征,用于预测透明细胞肾细胞癌的预后。

Identification of an immune-related risk signature for predicting prognosis in clear cell renal cell carcinoma.

机构信息

Department of Urology, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Anhui Province Key Laboratory of Genitourinary Diseases, Anhui Medical University, Hefei, China.

出版信息

Aging (Albany NY). 2020 Feb 6;12(3):2302-2332. doi: 10.18632/aging.102746.

DOI:10.18632/aging.102746
PMID:32028264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7041771/
Abstract

Immune status affects the initiation and progression of clear cell renal cell carcinoma (ccRCC), the most common subtype of renal cell carcinoma. In this study, we identified an immune-related, five-gene signature that improves survival prediction in ccRCC. Patients were classified as high- and low-risk based on the signature risk score. Survival analysis showed differential prognosis, while principal component analysis revealed distinctly different immune phenotypes between the two risk groups. High-risk patients tended to have advanced stage, higher grade disease, and poorer prognoses. Functional enrichment analysis showed that the signature genes were mainly involved in the cytokine-cytokine receptor interaction pathway. Moreover, we found that tumors from high-risk patients had higher relative abundance of T follicular helper cells, regulatory T cells, and M0 macrophages, and higher expression of PD-1, CTLA-4, LAG3, and CD47 than low-risk patients. This suggests our gene signature may not only serve as an indicator of tumor immune status, but may be a promising tool to select high-risk patients who may benefit from immune checkpoint inhibitor therapy. Multivariate Cox regression analysis showed that the signature remained an independent prognostic factor after adjusting for clinicopathological variables, while prognostic accuracy was further improved after integrating clinical parameters into the analysis.

摘要

免疫状态影响透明细胞肾细胞癌(ccRCC)的发生和进展,ccRCC 是肾细胞癌最常见的亚型。在本研究中,我们确定了一个与免疫相关的五基因特征,该特征可改善 ccRCC 的生存预测。根据特征风险评分,患者被分为高风险和低风险组。生存分析显示出不同的预后,而主成分分析显示出两组之间明显不同的免疫表型。高风险患者往往处于晚期、疾病分级较高且预后较差。功能富集分析表明,特征基因主要参与细胞因子-细胞因子受体相互作用途径。此外,我们发现高风险患者的肿瘤中滤泡辅助 T 细胞、调节性 T 细胞和 M0 巨噬细胞的相对丰度较高,PD-1、CTLA-4、LAG3 和 CD47 的表达水平也较高。这表明我们的基因特征不仅可以作为肿瘤免疫状态的指标,还可能是选择可能从免疫检查点抑制剂治疗中获益的高危患者的有前途的工具。多变量 Cox 回归分析表明,在调整临床病理变量后,该特征仍然是一个独立的预后因素,而在将临床参数纳入分析后,预后准确性进一步提高。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/011c1b2eb02a/aging-12-102746-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/8c5ea72a826a/aging-12-102746-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/0249201e4ec5/aging-12-102746-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/ba84659227bb/aging-12-102746-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/814dd818cf95/aging-12-102746-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/6abdee144895/aging-12-102746-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/75b3b9b9abc6/aging-12-102746-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/011c1b2eb02a/aging-12-102746-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/8c5ea72a826a/aging-12-102746-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/0249201e4ec5/aging-12-102746-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/ba84659227bb/aging-12-102746-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/814dd818cf95/aging-12-102746-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/6abdee144895/aging-12-102746-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/75b3b9b9abc6/aging-12-102746-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/67f0/7041771/011c1b2eb02a/aging-12-102746-g007.jpg

相似文献

1
Identification of an immune-related risk signature for predicting prognosis in clear cell renal cell carcinoma.鉴定一个免疫相关的风险特征,用于预测透明细胞肾细胞癌的预后。
Aging (Albany NY). 2020 Feb 6;12(3):2302-2332. doi: 10.18632/aging.102746.
2
Immune infiltration in renal cell carcinoma.肾细胞癌中的免疫浸润。
Cancer Sci. 2019 May;110(5):1564-1572. doi: 10.1111/cas.13996. Epub 2019 Apr 7.
3
Identification of tumor-antigen signatures and immune subtypes for messenger RNA vaccine selection in advanced clear cell renal cell carcinoma.鉴定晚期透明细胞肾细胞癌信使 RNA 疫苗选择的肿瘤抗原特征和免疫亚型。
Surgery. 2024 Sep;176(3):785-797. doi: 10.1016/j.surg.2024.04.027. Epub 2024 Jun 8.
4
Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.构建具有预后意义的新型免疫相关 lncRNA 对用于肾透明细胞肾细胞癌。
Dis Markers. 2021 Sep 1;2021:8800358. doi: 10.1155/2021/8800358. eCollection 2021.
5
SHC1 serves as a prognostic and immunological biomarker in clear cell renal cell carcinoma: a comprehensive bioinformatics and experimental analysis.SHC1 作为透明细胞肾细胞癌的预后和免疫生物标志物:全面的生物信息学和实验分析。
Sci Rep. 2024 Aug 30;14(1):20150. doi: 10.1038/s41598-024-70897-3.
6
The JAK-STAT signaling-related signature serves as a prognostic and predictive biomarker for renal cell carcinoma immunotherapy.JAK-STAT 信号相关特征可作为肾细胞癌免疫治疗的预后和预测生物标志物。
Gene. 2024 Nov 15;927:148719. doi: 10.1016/j.gene.2024.148719. Epub 2024 Jun 23.
7
A novel 10 glycolysis-related genes signature could predict overall survival for clear cell renal cell carcinoma.一种新型的 10 个糖酵解相关基因特征可预测透明细胞肾细胞癌的总生存期。
BMC Cancer. 2021 Apr 9;21(1):381. doi: 10.1186/s12885-021-08111-0.
8
A novel prognostic model based on immunogenomics for clear cell renal cell carcinoma.基于免疫基因组学的透明细胞肾细胞癌新型预后模型。
Int Immunopharmacol. 2021 Jan;90:107119. doi: 10.1016/j.intimp.2020.107119. Epub 2020 Nov 24.
9
Tumor-associated Macrophage-derived Interleukin-23 Interlinks Kidney Cancer Glutamine Addiction with Immune Evasion.肿瘤相关巨噬细胞衍生的白细胞介素-23 将肾癌的谷氨酰胺成瘾与免疫逃避联系起来。
Eur Urol. 2019 May;75(5):752-763. doi: 10.1016/j.eururo.2018.09.030. Epub 2018 Oct 4.
10
A Risk Signature with Autophagy-Related Long Noncoding RNAs for Predicting the Prognosis of Clear Cell Renal Cell Carcinoma: Based on the TCGA Database and Bioinformatics.基于 TCGA 数据库和生物信息学的自噬相关长非编码 RNA 风险签名预测肾透明细胞癌预后
Dis Markers. 2021 May 7;2021:8849977. doi: 10.1155/2021/8849977. eCollection 2021.

引用本文的文献

1
Prediction of clear cell renal cell carcinoma prognosis based on an immunogenomic landscape analysis.基于免疫基因组图谱分析的透明细胞肾细胞癌预后预测
Heliyon. 2024 Aug 13;10(16):e36156. doi: 10.1016/j.heliyon.2024.e36156. eCollection 2024 Aug 30.
2
SHC1 serves as a prognostic and immunological biomarker in clear cell renal cell carcinoma: a comprehensive bioinformatics and experimental analysis.SHC1 作为透明细胞肾细胞癌的预后和免疫生物标志物:全面的生物信息学和实验分析。
Sci Rep. 2024 Aug 30;14(1):20150. doi: 10.1038/s41598-024-70897-3.
3
APOBEC3C-mediated NF-κB activation enhances clear cell renal cell carcinoma progression.

本文引用的文献

1
Gene Expression Microarray Data Meta-Analysis Identifies Candidate Genes and Molecular Mechanism Associated with Clear Cell Renal Cell Carcinoma.基因表达微阵列数据的荟萃分析鉴定出与肾透明细胞癌相关的候选基因和分子机制。
Cell J. 2020 Oct;22(3):386-393. doi: 10.22074/cellj.2020.6561. Epub 2019 Dec 15.
2
Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma.局部透明细胞肾细胞癌中免疫基因表达特征和肿瘤浸润免疫细胞的预后影响。
J Immunother Cancer. 2019 May 28;7(1):139. doi: 10.1186/s40425-019-0621-1.
3
Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma.
载脂蛋白B mRNA编辑酶催化多肽样3C介导的核因子κB激活促进肾透明细胞癌进展。
Mol Oncol. 2025 Jan;19(1):114-132. doi: 10.1002/1878-0261.13721. Epub 2024 Aug 26.
4
PD1/PD-L1 blockade in clear cell renal cell carcinoma: mechanistic insights, clinical efficacy, and future perspectives.透明细胞肾细胞癌中PD1/PD-L1阻断:机制见解、临床疗效及未来展望。
Mol Cancer. 2024 Jul 16;23(1):146. doi: 10.1186/s12943-024-02059-y.
5
Development of a CT-assessed adiposity nomogram for predicting outcome in localized ccRCC.建立 CT 评估的肥胖指标预测局限性 ccRCC 患者预后的列线图
Abdom Radiol (NY). 2024 Oct;49(10):3485-3495. doi: 10.1007/s00261-024-04403-8. Epub 2024 Jun 6.
6
Analysis of the Tumor Immune Microenvironment (TIME) in Clear Cell Renal Cell Carcinoma (ccRCC) Reveals an M0 Macrophage-Enriched Subtype: An Exploration of Prognostic and Biological Characteristics of This Immune Phenotype.透明细胞肾细胞癌(ccRCC)肿瘤免疫微环境(TIME)分析揭示一种富含M0巨噬细胞的亚型:对这种免疫表型的预后和生物学特征的探索
Cancers (Basel). 2023 Nov 22;15(23):5530. doi: 10.3390/cancers15235530.
7
A CT-based deep learning radiomics nomogram outperforms the existing prognostic models for outcome prediction in clear cell renal cell carcinoma: a multicenter study.基于 CT 的深度学习放射组学列线图在预测透明细胞肾细胞癌预后方面优于现有预后模型:一项多中心研究。
Eur Radiol. 2023 Dec;33(12):8858-8868. doi: 10.1007/s00330-023-09869-6. Epub 2023 Jun 30.
8
SERPINE1 and its co-expressed genes are associated with the progression of clear cell renal cell carcinoma.丝氨酸蛋白酶抑制剂 1 及其共表达基因与肾透明细胞癌的进展相关。
BMC Urol. 2023 Mar 23;23(1):43. doi: 10.1186/s12894-023-01217-6.
9
Prognostic role of the innate immune signature CD163 and "eat me" signal calreticulin in clear cell renal cell carcinoma.先天免疫特征 CD163 和“吃我”信号钙网蛋白在肾透明细胞癌中的预后作用。
Cancer Immunol Immunother. 2023 Jun;72(6):1779-1788. doi: 10.1007/s00262-023-03369-8. Epub 2023 Jan 17.
10
Identification and Validation of the Prognostic Panel in Clear Cell Renal Cell Carcinoma Based on Resting Mast Cells for Prediction of Distant Metastasis and Immunotherapy Response.基于静止肥大细胞的透明细胞肾细胞癌预后标志物的鉴定和验证,用于预测远处转移和免疫治疗反应。
Cells. 2023 Jan 1;12(1):180. doi: 10.3390/cells12010180.
局限性和局部进展期肾细胞癌免疫治疗的现状
J Oncol. 2019 Apr 1;2019:7309205. doi: 10.1155/2019/7309205. eCollection 2019.
4
Construction and Validation of a 9-Gene Signature for Predicting Prognosis in Stage III Clear Cell Renal Cell Carcinoma.用于预测Ⅲ期透明细胞肾细胞癌预后的9基因标志物的构建与验证
Front Oncol. 2019 Mar 19;9:152. doi: 10.3389/fonc.2019.00152. eCollection 2019.
5
Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma.TP53 相关免疫预后模型在肝细胞癌中的建立和验证。
EBioMedicine. 2019 Apr;42:363-374. doi: 10.1016/j.ebiom.2019.03.022. Epub 2019 Mar 16.
6
Construction of immune-related risk signature for renal papillary cell carcinoma.构建肾乳头细胞癌免疫相关风险特征。
Cancer Med. 2019 Jan;8(1):289-304. doi: 10.1002/cam4.1905. Epub 2018 Dec 5.
7
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.全球癌症统计数据 2018:GLOBOCAN 对全球 185 个国家/地区 36 种癌症的发病率和死亡率的估计。
CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12.
8
Patient inflammatory status and CD4+/CD8+ intraepithelial tumor lymphocyte infiltration are predictors of outcomes in high-grade serous ovarian cancer.患者炎症状态和 CD4+/CD8+上皮内肿瘤淋巴细胞浸润是高级别浆液性卵巢癌结局的预测因素。
Gynecol Oncol. 2018 Oct;151(1):10-17. doi: 10.1016/j.ygyno.2018.07.025. Epub 2018 Aug 2.
9
Genomic Analysis of Tumor Microenvironment Immune Types across 14 Solid Cancer Types: Immunotherapeutic Implications.肿瘤微环境免疫类型的基因组分析在 14 种实体瘤中的应用:免疫治疗意义。
Theranostics. 2017 Aug 22;7(14):3585-3594. doi: 10.7150/thno.21471. eCollection 2017.
10
Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma.帕唑帕尼辅助治疗对比安慰剂用于局限性或局部进展性肾细胞癌患者肾切除术后的随机III期试验
J Clin Oncol. 2017 Dec 10;35(35):3916-3923. doi: 10.1200/JCO.2017.73.5324. Epub 2017 Sep 13.